Contingency

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
Well, Hypersensitivity, Research, GMP, Myelocyte, Eosinophilic esophagitis, Allergy, CSU, Rockefeller University, Contingency, UAS7, Survival, American Academy, EAACI, Omalizumab, G&A, B cell, Cell, Hives, PN, Prurigo, KIT, ILT4, Patient, Physician, Annual general meeting, AAAAI, SD, Prurigo nodularis, Digital, R, PD-1, Therapy, IND, Skin, D, Rare-earth element, Pharmaceutical industry, Vaccine, Aluminium, Cryptocurrency, Dermatology

HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • “This quarter, we were excited to report additional positive data from our barzolvolimab Phase 1b multi-dose study in chronic spontaneous urticaria.
  • Celldex plans to initiate a Phase 2 international trial of barzolvolimab in eosinophilic esophagitis (EoE), the most common type of eosinophilic gastrointestinal disease, in June of 2023.
  • Revenues: Total revenue was $1.0 million in the first quarter of 2023, compared to $0.2 million for the comparable period in 2022.

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, March 16, 2023
Gene editing, BCMA, Research and development, IND World's Fair Line, Stem cell, Development, Culture, Cancer, Bangladesh Technical Education Board, CD47, Epithelium, ADA, Hepatocyte, State Administrative Expenses, CAR, ISSCR, CD19, Cell, Success, Immune system, Diabetes, Research, CD22, AACR, Lymphoid leukemia, NIH, Patient, ASH, Safety, Letter, Contingency, Retinal pigment epithelium, Serum, Survival, SANA, Autoimmunity, Administration, Immunosuppression, Fusome, Investment, GAAP, Disease, Biotechnology, IND, Mobile phone, Pharmaceutical industry, Vaccine, Cryptocurrency, Beam

SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
  • Sana expects an investigator sponsor trial using primary human hypoimmune-modified islet cells transplanted in type 1 diabetes patients to begin later this year.
  • In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 3, 2023
Workforce, Exercise, Sale, FDA, Eye, CHASE, GAAP, Retinitis pigmentosa, ATM, D, R, Bank statement, Food, Stargardt disease, Secretome, Stem cell, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Biologics license application, Marketing, Acquisition, QID, Table, Net, BLA, SG, Safety, Depreciation, Contingency, Cornea, Orphan, KALA, Stargardt, Loss, IPR, Patient, Commercial, Pharmaceutical industry, Video game, Security (finance), Bank, Cryptocurrency, Fine chemical, Life insurance, Insurance, Alcon

ARLINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Kala is targeting top-line safety and efficacy data from the CHASE Phase 2b clinical trial in the first quarter of 2024.
  • In December 2022, Kala closed a private placement financing, raising aggregate gross proceeds of $31.0 million.
  • Fourth Quarter 2022 Financial Results:
    Net Product Revenues: Kala did not recognize product revenues in the fourth quarter of 2022, following the sale of its commercial portfolio to Alcon on July 8, 2022.
  • Cost of Product Revenues: Kala did not record cost of product revenues in the fourth quarter of 2022 following the sale of its commercial portfolio to Alcon on July 8, 2022.

CHESS Health Enhances its eRecovery Solution for Substance Use Disorder with Contingency Management Module

Retrieved on: 
Thursday, March 2, 2023
Health, Connections, Motivation, CBT, Arbor Place, EST, Element, Reward, Contingency, SUD, CHESS, Risk, Anxiety, CM, Cognitive behavioral therapy, Physician, Pharmaceutical industry, Management, Nursing

Rochester, NY, March 02, 2023 (GLOBE NEWSWIRE) -- CHESS Health , the leading provider of evidence-based digital health solutions addressing substance use disorder (SUD), today announced the addition of a Rewards module to its clinically proven eRecovery solution.

Key Points: 
  • Rochester, NY, March 02, 2023 (GLOBE NEWSWIRE) -- CHESS Health , the leading provider of evidence-based digital health solutions addressing substance use disorder (SUD), today announced the addition of a Rewards module to its clinically proven eRecovery solution.
  • This practice, often referred to as contingency management (CM), has been shown to positively impact SUD treatment outcomes.
  • “Addiction is incredibly difficult,” said Hans Morefield, Chief Executive Officer, CHESS Health.
  • The new module is available through the CHESS Health Connections mobile app or as a standalone option.

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
Well, GUF, GMP, IND, UAS7, AAAAI, Allergy, Patient, B cell, Cold urticaria, Inflammation, Research, Prurigo nodularis, R, Hypersensitivity, SRS, SD, Rockefeller University, D, ILT4, G&A, UCT, Prurigo, PD-1, Cell, Kinetics, Myelocyte, Aes, Growth, Hives, Gilead Sciences, Safety, American Academy, Eosinophilic esophagitis, Skin, KIT, Survival, Disease, CSU, Drug development, Annual general meeting, Omalizumab, Contingency, Pharmaceutical industry, Vaccine, Aluminium, Mineral wool, Cryptocurrency, Dermatology

HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
  • Celldex believes her deep background in drug development strongly complements the current Board’s skills and experiences.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • The litigation settlement related loss had a ($0.32) impact on net loss per share for the twelve months ended December 31, 2022.

Contingency Capital Holds Final Closing of First Commingled Fund

Retrieved on: 
Tuesday, December 20, 2022
Contingency, Investment, Institutionalisation, Consultant, Security (finance)

NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Contingency Capital, a global asset management business focused on credit-oriented legal assets, has successfully completed the capital raise for its first commingled fund, with over $490 million in new discretionary capital across the fund and related managed accounts.

Key Points: 
  • NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Contingency Capital, a global asset management business focused on credit-oriented legal assets, has successfully completed the capital raise for its first commingled fund, with over $490 million in new discretionary capital across the fund and related managed accounts.
  • The firm launched in November 2020 and has raised and deployed in excess of $700 million across a series of strategies and transactions.
  • Brandon Baer, Founder and Chief Investment Officer of Contingency Capital, stated: "We are very grateful for the support our business has received from institutional investors in the United States and Europe.
  • The firm combines litigation expertise with a fundamental credit approach, building structured, diversified pools of legal assets to create sustainable, credit-like returns.

Military power: U.S. Army chooses resilient lead batteries "to deploy energy storage systems anywhere in the world"

Retrieved on: 
Tuesday, October 18, 2022
Paragon, Corps, Engineer, United States Army Command, Control, Communication, Computers, Cyber, Intelligence, Surveillance and Reconnaissance Center, Government, Carbon footprint, Telecommunication, Hurricane Maria, Army of the United States, ABC, ESS, Carbon, ERDC, Research, U.S. Department of Defense Strategy for Operating in Cyberspace, Multimedia, Technology, Unitary state, U.S. Army Corps of Engineers, Europe District, CBI Bank & Trust, EnerSys, Department, Military personnel, Fort Leonard Wood, Consortium, Space Innovation and Development Center, CMG, Federal government of the United States, Safety, CBI, CEED, United States Army Corps of Engineers, Construction, Raiford, NATO, Contingency, Lead, Weather, Army, View, Gasoline, Satellite navigation device, Renewable energy, Electric battery, Environment, United States Army

DURHAM, N.C., Oct. 18, 2022 /PRNewswire/ -- The U.S. Army has chosen advanced lead battery energy storage systems to enhance its operational effectiveness in disaster zones and in combat.

Key Points: 
  • DURHAM, N.C., Oct. 18, 2022 /PRNewswire/ -- The U.S. Army has chosen advanced lead battery energy storage systems to enhance its operational effectiveness in disaster zones and in combat.
  • "Lead batteries give us the ability to deploy energy storage systems anywhere in the world, enhancing our resiliency.
  • Using lead batteries would provide Army Commanders with local sources of batteries in vehicles and telecommunications towers around the world.
  • The prototype lead battery energy storage systems will be constructed and tested in various simulated duty cycles to recreate typical field conditions for military operations.

3 Greenberg Traurig Attorneys Named to ABA Public Contract Law Section Leadership Positions

Retrieved on: 
Thursday, September 8, 2022
Transfer, American Bar Association, Software, American Bar Association Model Rules of Professional Conduct, Research, False Claims Act, Battlespace, Contingency, Cooperative research and development agreement, Telecommunication, Small business, Government, NLJ, LLP, Solution, Center for Resource Solutions, Department of Defense Office of Inspector General, Topical steroid withdrawal, McQuade, Department, Intellectual Property Committee, Information technology, Lawyer, Public Contract Law Journal, AM, Center, Office of Inspector General (United States), Leadership, Federal Information Technology Acquisition Reform Act, Compliance, Defense, IP, Cooperative, Debarment, Acquisition, Growth, Contract, ABA, Practice of law, Management, Property management, Khoo Swee Chiow, Greenberg Traurig

WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- Three Greenberg Traurig, LLP attorneys, Jeffery M. Chiow, Paul F. McQuade, and Melissa P. Prusock, were appointed to leadership positions within the American Bar Association (ABA)'s Section of Public Contract Law.

Key Points: 
  • Three Greenberg Traurig, LLP attorneys, Jeffery M. Chiow, Paul F. McQuade, and Melissa P. Prusock, were appointed to leadership positions within the American Bar Association (ABA)'s Section of Public Contract Law.
  • WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- Three Greenberg Traurig, LLP attorneys, Jeffery M. Chiow , Paul F. McQuade , and Melissa P. Prusock , were appointed to leadership positions within the American Bar Association (ABA)'s Section of Public Contract Law.
  • The Greenberg Traurig lawyers appointed to ABA leadership positions include:
    Chiow, who has held numerous ABA leadership positions over the years, was named co-chair of the ABA's Acquisition Reform & Emerging Issues Committee and vice chair of its Legislative & Regulatory Coordinating and Battlespace & Contingency Procurements committees.
  • About Greenberg Traurig: Greenberg Traurig, LLP has more than 2500 attorneys in 43 locations in the United States, Europe, Latin America, Asia, and the Middle East.

Private Sector Stakeholders release Joint Statement Calling for Increased Public Private Collaboration

Retrieved on: 
Tuesday, June 7, 2022
Exercise, MCAC, Leadership, Cyberspace Solarium Commission, Solar Winds, Coalition, Reach, Joint, Log4j, Multilateral, RET, Business Executives for National Security, Cyberspace, Computer security, CEO, Partnership, Policy, Security, Government, CISA, Organization, Officer, Investment, Private sector, Alliance, Impact, Midmarket Institute, Contingency, Cybersecurity and Infrastructure Security Agency, National security, Institute, National, Law, Committee, Weapon, Risk management, Technology

In the United States, we think the joint statement highlights the current successes of the Joint Cyber Defense Collaborative, as well as it's need to continue to grow and evolve.

Key Points: 
  • In the United States, we think the joint statement highlights the current successes of the Joint Cyber Defense Collaborative, as well as it's need to continue to grow and evolve.
  • The signatory organizations believe that the Biden administration has made progress in deepening partnership with the private sector to improve the security of the country's critical infrastructure.
  • Effective engagement requires private and public sector collaboration and leadership to address issues such as the Solar Winds supply chain attack, log4J vulnerabilities, ransomware attacks, and threats from Russian and other malicious nation-state actors.
  • Building Teamwork: The signatory organizations propose expanded opportunities for long-term exchange programs between government and private sector technical personnel in cybersecurity roles.

Greenberg Traurig Adds Jeffery M. Chiow to Government Contracts Practice in Washington, D.C.

Retrieved on: 
Friday, March 18, 2022
Private law, Risk, False Claims Act, LLP, Public Contract Law Journal, Congress, Contract, United States Department of Justice, Government, AM, NLJ, Cloud computing, Compliance, Project, George Washington University Law School, Weapon, United States service academies, United States Department of Defense, Pro bono, Carbon, Industry, CMMC, Intellectual property, Marines, George, Defense, Chambers, DOJ, American Bar Association Model Rules of Professional Conduct, American Bar Association, Information technology, Solution, Department, GT, Contingency, Telecommunication, Lawyer, Battlespace, Acquisition, Insurance, D.C, Greenberg Traurig

WASHINGTON, March 18, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP has added Jeffery M. Chiow as a shareholder in its Government Contracts & Projects Practice.

Key Points: 
  • WASHINGTON, March 18, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP has added Jeffery M. Chiow as a shareholder in its Government Contracts & Projects Practice.
  • Chiow joins from Rogers, Joseph, O'Donnell, PC where he was co-chair of the firm's Government Contracts Practice .
  • "I'm thrilled to join Greenberg Traurig, whose platform exponentially expands my ability to respond to client needs," Chiow said.
  • About Greenberg Traurig's Government Contracts & Projects Practice: Greenberg Traurig's Government Contracts & Projects Practice helps companies navigate the highly regulated acquisition and compliance processes of federal, state, local, and foreign governments and their agencies.